Hey @RaceOncology,
Just a quick query - I thought I had a handle on this but a gap in my understanding has popped up when I was challenged on FTO inhibition today.
Given the universal nature of m6a modification within the mRNA epitranscriptome realm:
1. How is Zantrene delivered such that is only targets cancerous cells and does not impact FTO levels/normal m6a demethylation levels in adjacent tissue/cells
2. if Zantrene is unable to be exceptionally accurately delivered to ONLY target cells, what impact on adjacent healthy cell function could be expected if Zantrene downregulates FTO in this tissue?
@Mason14 has posted a paper showing that human foetal development was still achievable with no FTO levels whatsoever due to a genetic defect - so curious to see what we’d expect to see if we deprived healthy adjacent tissue due to collateral impact.
Thanks!
- Forums
- ASX - By Stock
- RAC
- Pillar 1 - FTO (new thread)
Pillar 1 - FTO (new thread), page-1720
-
-
- There are more pages in this discussion • 1,220 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.84 |
Change
-0.025(1.34%) |
Mkt cap ! $313.3M |
Open | High | Low | Value | Volume |
$1.89 | $1.91 | $1.81 | $257.6K | 138.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 26825 | $1.84 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.90 | 759 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 26825 | 1.840 |
1 | 7989 | 1.815 |
1 | 14750 | 1.810 |
1 | 759 | 1.805 |
3 | 1837 | 1.800 |
Price($) | Vol. | No. |
---|---|---|
1.900 | 759 | 1 |
1.905 | 496 | 1 |
1.910 | 2500 | 1 |
1.915 | 1000 | 1 |
1.920 | 10000 | 1 |
Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online